{"id":"NCT01704755","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","officialTitle":"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-01","completion":"2014-09","firstPosted":"2012-10-11","resultsPosted":"2015-01-06","lastUpdate":"2021-07-12"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection","Compensated Cirrhosis"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267, ABT-333","otherNames":["Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":[]}],"arms":[{"label":"ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks","type":"EXPERIMENTAL"},{"label":"ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks","deltaMin":91.8,"sd":null},{"arm":"ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks","deltaMin":96.5,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24725237","29377566","26248955"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":208},"commonTop":["FATIGUE","HEADACHE","NAUSEA","PRURITUS","INSOMNIA"]}}